Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Biagio Ricciuti; Arielle Elkrief; Joao V. Alessi; Xinan Wang; Yvonne Li; Hersh Gupta; Daniel M. Muldoon; Arrien A. Bertram; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Adriana Barrichello; Victor R. Vaz; Malini Gandhi; Elinton Lee; Geoffrey I. Shapiro; Hyesun Park; Mizuki Nishino; James Lindsay; Kristen D. Felt; Bijaya Sharma; Andrew D. Cherniack; Scott J. Rodig; Daniel R. Gomez; Narek Shaverdian; Mehrdad Rakaee; Chaitanya Bandlamudi; Marc Ladanyi; Pasi A. Jänne; Adam J. Schoenfeld; Lynette M. Sholl; Mark M. Awad; Michael L. Cheng

doi:10.1158/1078-0432.27031210.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricciuti et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523abf https://doi.org/10.1158/1078-0432.27031210.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading